Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;141(3):388-400.
doi: 10.1111/imm.12201.

CD49a promotes T-cell-mediated hepatitis by driving T helper 1 cytokine and interleukin-17 production

Affiliations

CD49a promotes T-cell-mediated hepatitis by driving T helper 1 cytokine and interleukin-17 production

Yonglin Chen et al. Immunology. 2014 Mar.

Abstract

It is becoming increasingly clear that the T-cell-mediated immune response is important in many diseases. In this study, we used concanavalin A (Con A) -induced hepatitis to investigate the role of CD49a in the molecular and cellular mechanism of the T-cell-mediated immune response. We found that CD49a(-/-) mice had significantly reduced levels of serum alanine aminotransferase and were protected from Con A-induced hepatitis. CD49a deficiency led to decreased production of interferon-γ (IFN-γ) and interleukin-17A (IL-17A) after Con A injection. Furthermore, we found that hepatic CD4(+) T cells and invariant natural killer T cells up-regulated CD49a expression, along with enhanced activation after Con A injection, leading to production of inflammatory cytokines by these T cells. Blockade of CD49a in vivo ameliorated Con A-induced hepatitis with reduced production of IFN-γ and IL-17A. Hence, CD49a promoted Con A-induced hepatitis through enhancing inflammatory cytokine production (IFN-γ and IL-17A) by CD4(+) T and invariant natural killer T cells. The protective effect of CD49a blockade antibody suggested a new target therapeutic molecule for intervention of T-cell-mediated liver injury.

Keywords: CD49a; T-cell-mediated hepatitis; interferon-γ; interleukin-17A.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CD49a deficiency ameliorates concanavalin A (Con A) -induced hepatitis. (a) Survival of wild-type and CD49a−/− mice after injection with a lethal dose of Con A (25 μg/g). Survival was monitored every 6 hr. Data show the combined results from two experiments, n = 10 per group. (b) Serum alanine aminotransferase (ALT) levels of wild-type (n = 7 or n = 8) and CD49a−/− (n = 7 or n = 8) mice 24 hr after intravenous injection of Con A (12 μg/g). Data show the combined results from two experiments (mean ± SEM; *< 0·05; **< 0·01). (c) Representative photomicrographs of haematoxylin & eosin-stained liver sections from wild-type and CD49a−/− mice 12 and 24 hr after Con A injection. Black scale bars represent 50 μm. (d) The percentage of the necrotic area in the livers of wild-type and CD49a−/− mice 12 and 24 hr after Con A treatment (12 μg/g). The percentage of the necrotic area was measured from three different fields for each mouse (n = 7 or n = 8 mice/group; mean ± SEM; ***< 0·001). (e) Representative photomicrographs of liver sections stained with anti-CD45 (brown) from wild-type and CD49a−/− mice 12 hr after Con A injection (12 μg/g). Black scale bars represent 50 μm.
Figure 2
Figure 2
Serum interferon-γ (IFN-γ) and interleukin-17A (IL-17A) levels decrease in CD49a−/− mice after concanavalin A (Con A) injection. Wild-type (n = 6–10) and CD49a−/− mice (n = 6–10) were intravenously injected with Con A (12 μg/g). The serum levels of IFN-γ (a), IL-17A (b), tumour necrosis factor-α (TNF-α) (c), IL-4 (d), IL-10 (e), IL-2 (f) and IL-6 (g) in wild-type (black bars) and CD49a−/− (white bars) mice were detected by ELISA at the indicated time-points (6 and 12 hr) after Con A injection. Data show the combined results from two experiments (mean ± SEM; *< 0·05).
Figure 3
Figure 3
CD49a deficiency decreases production of inflammatory cytokines in vitro. (a) Representative Western blotting of type IV collagen in the livers of untreated wild-type and CD49a−/− mice. n = 3 per group. (b) Liver mononuclear cells were prepared from untreated wild-type (black bars) and CD49a−/− mice (white bars). Cells were stimulated with concanavalin A (Con A) for 24 hr in 96-well plates pre-coated with type IV collagen. Culture supernatants were collected and assayed for interferon-γ (IFN-γ) and interleukin-17A (IL-17A) production by ELISA. Data are expressed as the mean ± SEM from quintuplicate samples (***< 0·001). Data are representative of two independent experiments. (c) Liver mononuclear cells were isolated from untreated wild-type (black bars) and CD49a−/− mice (white bars) and cultured under T helper type 1 (Th1) or Th17 cell-polarizing conditions in the presence of anti-CD3/28 antibodies for 72 hr in 96-well plates pre-coated with type IV collagen. Data are expressed as the mean ± SEM from quadruplicate samples (***< 0·001). Data are representative of two independent experiments.
Figure 4
Figure 4
CD49a deficiency does not influence mononuclear cell infiltration. Wild-type and CD49a−/− mice were intravenously injected with concanavalin A (Con A) (12 μg/g). Liver mononuclear cells were isolated 6 hr after injection. Absolute numbers of invariant natural killer T (iNKT) (CD1d tetramer+ CD3int), CD4+ T (CD1d tetramer CD3hi CD4+), CD8+ T (CD3hi CD8+), NK (NK1.1+ CD3), B (CD19+ CD3), macrophage (CD11b+ F4/80+) and inflammatory monocytes (IM) (CD11b+ Ly6Chi) cells in the livers of wild-type (n = 8, black bars) versus CD49a−/− (n = 7–8, white bars) mice were calculated. Data show the combined results from two experiments (mean ± SEM).
Figure 5
Figure 5
CD49a expression on hepatic CD4+ T cells during concanavalin A (Con A) -induced hepatitis. (a) CD49a expression on liver CD4+ T (CD1d tetramer CD3hi CD4+) cells from untreated wild-type and CD49a−/− mice. Data are representative of two independent experiments, n = 8 per group. Grey-filled curves, isotype control. (b) CD49a expression on liver CD4+ T (CD1d tetramer CD3hi CD4+) cells from saline-treated (black solid line) or Con A-treated (12 μg/g, dashed line) wild-type mice 6 hr post-injection. Data are representative of two independent experiments, n = 8 per group. Grey-filled curves, isotype control. (c) Absolute number of CD49a+ CD4+ T (CD49a+ CD1d tetramer CD3hi CD4+) cells in the livers of saline-treated (white bar) or Con A-treated (12 μg/g, black bar) wild-type mice 6 hr after injection. Data show the combined results from two experiments, n = 8 per group (mean ± SEM; *< 0·05). (d) Expression of CD69 and CD25 on hepatic CD4+ T (CD1d tetramer CD3hiCD4+) cells from wild-type (black solid line) and CD49a−/− mice (dashed line) 6 hr after Con A injection (12 μg/g). Data are representative of two independent experiments, n = 8–9 per group. Grey-filled curves, isotype control.
Figure 6
Figure 6
Decreased production of CD4+ T-cell-derived interferon-γ (IFN-γ) and interleukin-17A (IL-17A) in CD49a−/− mice. Wild-type and CD49a−/− mice were intravenously injected with concanavalin A (Con A) (12 μg/g). Liver mononuclear cells were isolated 12 hr after Con A treatment. (a) CD49a expression on liver IFN-γ+ CD4+ T (IFN-γ+ CD1d tetramer CD3hi CD4+, left) cells and IL-17A+ CD4+ T (IL-17A+ CD1d tetramer CD3hi CD4+, right) cells from wild-type mice. Data are representative of two independent experiments, n = 6 per group. Grey-filled curves, isotype control. (b) Intracellular staining of IFN-γ and IL-17A in liver CD4+ T (CD1d tetramer CD3hi CD4+) cells. Numbers indicate percentages. (c) Statistical analysis of the percentage of IFN-γ+ cells (left) and mean fluorescence intensity (MFI) of IFN-γ (right) in liver CD4+ T (CD1d tetramer CD3hi CD4+) cells. (d) Statistical analysis of the percentage of IL-17A+ cells (left) and MFI of IL-17A (right) in liver CD4+ T (CD1d tetramer CD3hi CD4+) cells. Data show the combined results from two experiments, n = 8 per group (mean ± SEM; **< 0·01; ***< 0·001).
Figure 7
Figure 7
CD49a expression on hepatic invariant natural killer T (iNKT) cells during concanavalin A (Con A) -induced hepatitis. (a) CD49a expression on liver iNKT (CD1d tetramer+ CD3int) cells from untreated wild-type and CD49a−/− mice. Data are representative of two independent experiments, n = 8 per group. Grey-filled curves, isotype control. (b) CD49a expression on liver iNKT (CD1d tetramer+ CD3int) cells from saline-treated (black solid line) or Con A-treated (12 μg/g, dashed line) wild-type mice 6 hr post-injection. Data are representative of two independent experiments, n = 8 per group. Grey-filled curves, isotype control. (c) Expression of Fas ligand and TRAIL on liver iNKT (CD1d tetramer+ CD3int) cells from wild-type mice (black solid line) and CD49a−/− mice (dashed line) 6 hr after Con A injection (12 μg/g). Data are representative of two independent experiments, n = 9 per group. Grey-filled curves, isotype control.
Figure 8
Figure 8
Invariant natural killer T (iNKT) -cell-derived interferon-γ (IFN-γ) and interleukin-17A (IL-17A) are reduced in CD49a−/− mice. Wild-type mice (black bars) and CD49a−/− mice (white bars) were intravenously injected with concanavalin A (Con A) (12 μg/g). Liver mononuclear cells were isolated 12 hr after Con A treatment. (a) CD49a expression on liver IFN-γ+ iNKT (IFN-γ+ CD1d tetramer+ CD3int, left) cells and IL-17A+ iNKT (IL-17A+ CD1d tetramer+ CD3int, right) cells from wild-type mice. Data are representative of two independent experiments, n = 6 per group. Grey-filled curves, isotype control. (b) Intracellular staining of IFN-γ and IL-17A in liver iNKT (CD1d tetramer+ CD3int) cells. Numbers indicate percentages. (c) Statistical analysis of the percentage of IFN-γ+ cells (left) and mean fluorescence intensity (MFI) of IFN-γ (right) in liver iNKT (CD1d tetramer+ CD3int) cells. (d) Statistical analysis of the percentage of IL-17A+ cells (left) and MFI of IL-17A (right) in liver iNKT (CD1d tetramer+ CD3int) cells. Data show the combined results from two experiments, n = 8 per group (mean ± SEM; *< 0·05; **< 0·01; ***< 0·001).
Figure 9
Figure 9
Blockade of CD49a attenuates concanavalin A (Con A) -induced liver injury. Wild-type mice were pretreated with 100 μg of either isotype antibody (black bars) or anti-CD49a monoclonal antibody (Ha31/8, white bars) per mouse 24 hr before Con A (12 μg/g) injection. Blood and liver tissues were collected 12 hr after Con A injection. (a) Serum alanine aminotransferase (ALT) levels were detected. (b) Representative photomicrographs of haematoxylin & eosin (H&E) -stained liver sections. Black scale bars represent 50 μm. (c) The percentage of the necrotic area in the livers 12 hr after Con A treatment was calculated by analysing H&E-stained sections. The percentage of necrotic area was measured from three different fields for each mouse (n = 9 mice/group). (d) Serum interferon-γ (IFN-γ) levels were detected by ELISA. (e) Serum interleukin-17A (IL-17A) levels were detected by ELISA. Data show the combined results from two experiments, n = 9 per group (mean ± SEM; *< 0·05,***< 0·001).

Similar articles

Cited by

References

    1. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. 1992;90:196–203. - PMC - PubMed
    1. Zhang S, Liang R, Luo W, et al. High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-γ dysregulation of CD4+ T cells. Hepatology. 2012;57:1620–31. - PubMed
    1. Takeda K, Hayakawa Y, Kaer Van L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97:5498–503. - PMC - PubMed
    1. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, Nakayama T, Taniguchi M. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med. 2000;191:105–14. - PMC - PubMed
    1. Lafdil F, Wang H, Park O, et al. Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology. 2009;137:2125–35. e1.2. - PMC - PubMed

Publication types

MeSH terms